Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market Size, Analysis 2032

Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market Size, Analysis 2032

Segments - by Product Type (Portable Oxygen Concentrators and Stationary Oxygen Systems), by Delivery Devices (Nasal Cannulas, Oxygen Masks, Venturi Masks, Non-rebreather Masks), by Technology (Continuous Flow and Pulse Dose), by Patient Age (Pediatric and Adult)

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-7129 | 4.8 Rating | 91 Reviews | 304 Pages | Format : PDF Excel PPT

Report Description


Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market Outlook 2032

The global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market size was USD XX Billion in 2023 and is likely to reach USD XX Billion by 2032, expanding at a CAGR of XX% during 2024–2032. The market growth is attributed tothe increasing prevalence of COPD, primarily by smoking.

According to the WHO, COPD is projected to become the third leading cause of death worldwide by 2030. Cases of COPD are increasing daily due to the rise of risk factors such as smoking, air pollution, and occupational exposure to dust and hazardous chemicals. The surge in diagnosed cases has made oxygen therapy a cornerstone in the treatment of COPD.

  • Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021, approximately 5% of all global deaths.

    Chronic obstructive pulmonary disease (COPD) oxygen therapy market Outlook

COPD patients usually develop lung damage or phlegm accumulation. The symptoms of COPD include coughing, wheezing, and exhaustion. Oxygen therapy helps people with COPD breathe better and live longer. It is a well-established treatment for patients with severe resting hypoxemia, a condition in which blood oxygen levels drop while resting.

Oxygen therapy for COPD patients is aimed at increasing the amount of oxygen in the lungs and the bloodstream. Oxygen is delivered through a nasal cannula, facemask, or a tube that runs from an oxygen tank directly into the windpipe.

Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market Dynamics

Major Drivers

Technological advancements in oxygen therapy devices are a major market driver. The development of portable oxygen concentrators, which offer mobility and convenience for patients was a major innovation in the oxygen therapy market.

R&D efforts are focused on making devices small, lightweight, and capable of delivering continuous oxygen supply. Such devices are bound to improve the quality of life of patients. Developments in sensor technology and connectivity of empowered remote monitoring and management of oxygen therapy for COPD patients.


The global aging population is driving the market. With age, respiratory ailments such as COPD become frequent. According to the UN, the global population aged 60 years and over is expected to double by 2050. Elderly individuals are susceptible to COPD, further contributing to the market growth as they generally require long-term oxygen therapy.

The rising trend of home healthcare is contributing to the market growth. People are choosing home-based care for COPD treatment. The availability of portable oxygen concentrators has provided a boost to the COPD oxygen therapy market.

Demand for oxygen therapy consumables such as nasal cannulas, oxygen tanks, facemasks, humidifiers, and
pulse oximeters has surged in recent years. Manufacturers are not just focusing on the development of comfortable, long-term-use devices buton making the said devices compatible with a wide array of oxygen therapy devices as well.

Existing Restraints

The high cost of oxygen therapy is a significant market restraint. COPD is a chronic disease that requires long-term care and specialized treatment, both of which are expensive. Additionally, COPD isaccompanied by various other afflictions, increasing overall treatment costs.

This is a significant barrier, particularly for populations in Low- and Middle–income countries (LMIC). Additionally, the high costs affect healthcare providers as they struggle to cover the cost of treatment for a large number of patients.

This often leads to underdiagnosis and undertreatment, which results in restricted access to medications and medical devices at the cost of the patient’s access to sufficient healthcare.


The potential adverse effects of oxygen therapy hinder the market. Providing too much oxygen damages lung tissues, especially in patients afflicted with severe COPD. Continuous use of nasal cannulas causes dryness and irritation in the nasal passages.

Pressure points from oxygen delivery devices lead to skin irritation. Inadequate monitoring of oxygen saturation levelsleads to unnecessary oxygen use. Patients are likely to find oxygen masks or cannulas uncomfortable, leading to non-adherence to prescribed treatments. The need to carry oxygen equipment is burdensome and limiting to free mobility and activity levels for patients.

Emerging Opportunities

The development of innovative therapies and treatment approaches is creating new opportunities in the market. Most COPD treatments focus on managing symptoms and slowing the progression of the disease. There is a significant need for new and innovative measures to provide better patient outcomes in the face of the rising number of cases. Wearable devices and remote monitoring systems are some of the avenues opening up for research and development projects.

Further opportunities lie in developing innovative oxygen delivery systems, expanding the
telemedicine integration for patient monitoring, personalized treatment plans, initiatives for patient education, and improving market access in underserved regions.


Increasing adoption of home-based oxygen therapy solutions is expected to create lucrative opportunities for market players, driven by the desire for improved quality of life, reduced hospital stay, and low healthcare costs. Portable, user-friendly oxygen concentrators are being increasingly sought after.

Home-based oxygen therapy allows patients to supervise their condition in a comfortable and familiar environment, improving their adherence to prescribed treatment and raising patient morale and satisfaction. The sh
ift towards a patient-centric approach represents a substantial growth opportunity for manufacturers and providers of oxygen therapy devices, for the development of new innovative and user-friendly products.

Scope of the Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2023

Historic Data

2017 -2022

Forecast Period

2024–2032

Segmentation

Product Type (Portable Oxygen Concentrators and Stationary Oxygen Systems), Delivery Devices (Nasal Cannulas, Oxygen Masks, Venturi Masks, and Non-rebreather Masks), Technology (Continuous Flow and Pulse Dose), Patient Age (Pediatric and Adult), and End User (Hospital, Clinic, and Homecare)

Regional Scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast

Key Players Covered in the Report

Abbott; Drive DeVilbiss Healthcare; F. Hoffmann-La Roche Ltd; Fisher & Paykel Healthcare; GE Healthcare; GlaxoSmithKline (GSK plc.); Invacare Holdings Corporation; Nidek Medical Products, Inc.; Philips Respironics (Koninklijke Philips N.V.); and OMRON Healthcare

Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market Segment Insights

Product Type Segment Analysis

Based on product type, the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is divided into portable oxygen concentrators and stationary oxygen systems.

The stationary oxygen systems segment holds a major market share due to the high prevalence of COPD and the need for consistent oxygen delivery at home. The segment consists of large, non-portable oxygen concentrators that are designed to be used primarily at home, providing a continuous supply of oxygen to patients who typically stay in one location within their residence. Stationary oxygen systems offer greater oxygen output capacity to meet the needs of severe COPD cases.

Devices such as liquid oxygen devices and oxygen cylinders are widely used due to their reliability and accessibility, especially in regions with limited technologies. Oxygen cylinders come in different sizes, catering to a variety of patient needs and usage scenarios. The demand for this segment remains high, particularly in emergency and hospital settings.


The portable oxygen concentrators segment is expected to expand at a significant growth rate in the coming years, owing to the high demand for portable oxygen solutions that allow COPD patients to maintain mobility and independence while receiving necessary oxygen therapy, particularly when outside of home premises.

Portable oxygen concentrators (POCs) separate nitrogen and oxygen from air in the environment, discards nitrogen, and supplies 95% pure oxygen to patients through a mask.

POCs are smaller than stationary oxygen systems, allowing patients to carry the device easily. COPD patients often require long-term oxygen therapy, and POCs enable them to participate in daily activities without being tethered to a stationary oxygen source.

Chronic obstructive pulmonary disease (COPD) oxygen therapy market Type

Delivery Devices Segment Analysis

On the basis of delivery devices, the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is segregated into nasal cannulas, oxygen masks, venturi masks, and non-rebreather masks.

The nasal cannulas segment holds a large market share due to their ability to provide higher concentrations of oxygen comfortably and efficiently, especially during exacerbations of COPD. Nasal cannulas are considered one of the most prominent options for long-term oxygen therapy due to their comfort and ease of use compared to other delivery methods.

High-flow nasal cannulas allow for higher oxygen flow rates, which is crucial for managing severe COPD cases. The benefits of nasal cannulas include improved breathing, reduced fatigue, better sleep quality, and increased energy levels.


The venturi masks segment is anticipated to grow at a substantial CAGR during the forecast period, owing to their ability to deliver precise and controlled oxygen concentrations. This ability is crucial for managing COPD, where maintaining accurate oxygen saturation is vital.

There is a high demand for venturi masks as they deliver specific oxygen concentrations by mixing room air with oxygen through controlled mechanisms. Additionally, venturi masks come with color-coded attachments, allowing healthcare providers to select the appropriate oxygen concentration for each patient based on their individual needs.

Technology Segment Analysis

In terms of technology, the global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is segmented into continuous flow and pulse dose.The continuous flow segment dominated the market segment due to its effectiveness in managing severe COPD cases, usually achieved through portable oxygen concentrators with continuous flow technology.

Most patients with COPD require this method for optimal oxygen delivery. Continuous flow oxygen therapy is delivered through portable oxygen concentrators, allowing patients to maintain mobility while receiving the necessary oxygen. According to NIH, multiple research studies indicate that continuous flow oxygen therapy for COPD significantly improves patient quality of life, and potentially reduces mortality rates.


The pulse dose segment is projected to register a robust growth rate during the assessment years, as pulse dose systems are designed to be efficient, delivering oxygen only during the patient’s inhalation. This saves oxygen and reduces the size of portable oxygen concentrators or tanks.

Pulse dose is commonly used in patients with mild to moderate COPD who require supplemental oxygen during activity or rest, not constantly. The segment growth is driven by its cost-effectiveness, portability, technological advancements, and increasing adoption of home-based and oxygen therapy solutions.

Patient Age Segment Analysis

Based on patient age, the global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is divided into pediatric and adult. The adult segment generated a major revenue share of the market, owing to the high prevalence of COPD among older adults. Five million adults live with chronic lung disease in the US, with more than one million prescribed long-term oxygen therapy (LTOT).

LTOT involves continuous home oxygen use for significant periods (15 hours /day) to manage severe hypoxemia. Treatment options are being improved due to advancements in oxygen delivery technology, including portable oxygen concentrators which enhance patient outcomes and quality of life.


The pediatric segment is a smaller segment, bit still significant nevertheless. COPD is generally considered a disease primarily affecting adults. However, children with severe chronic lung conditions, often stemming from premature birth complications, still necessitate oxygen therapy.

Conditions such as bronchopulmonary dysplasia and cystic fibrosis are possible causes of chronic respiratory issues. Pediatric patients require specialized oxygen delivery devices and monitoring systems, designed to suit their smaller size and developmental needs. The availability of pediatric-specific solutions highlights the market’s commitment to address the needs of all COPD patients, irrespective of age.

End User Segment Analysis

In terms of end user, the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is divided into hospital, clinic, and homecare. The hospital segment holds a significant market share due to the acute care needs of severe COPD cases requiring hospitalization and the advanced monitoring capabilities available in hospital facilities.

Hospital-based oxygen therapy is essential for managing acute exacerbations, ensuring that patients receive intensive care to stabilize their condition. Hospitals see a substantial number of patients requiring oxygen therapy due to the prevalence of COPD. The segment is supported by advanced medical devices and trained healthcare professionals, able to manage complex COPD cases and oxygen therapy needs.


The homecare segment is often considered the fastest-growing segment within the overall COPD oxygen therapy market due to the increasing preference for home-based care. COPD is the primary condition driving demand for homecare oxygen therapy, as many COPD patients require long-term oxygen therapy at home to manage their symptoms and improve their quality of life.

The desire for a better quality of life, reduced hospital stays, and lower healthcare costs drive the segment. Home care allows patients to manage their condition in a comfortable and familiar environment, improving adherence to treatment and overall patient satisfaction.


Clinics are an important segment in the COPD oxygen therapy market. Clinics provide outpatient surgical and diagnostic services. The segment has seen surging demand with the growing number of clinics and the ability to deliver specialized care cost-effectively. Clinics offer a convenient and efficient alternative to hospitals, catering to patients who require short-term care of follow-ups after surgical procedures.

Chronic obstructive pulmonary disease (COPD) oxygen therapy market End-user

Regional Outlook

In terms of region, the global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

North America holds the largest share of the market due to the pervasiveness of COPD, increasing awareness about the benefits of oxygen therapy, and rapid advancements in technology. The large patient population, robust healthcare infrastructure, and research and development in respiratory healthcare technologies further augment the growth.

The Asia Pacific market is projected to grow at a significant pace in the coming years, driven by factors such as the rising prevalence of COPD due to lifestyle changes, the increasing geriatric population, and the expanding healthcare infrastructure across the region.

Countries such as China, India, and Japan are leading the market expansion, with technological advancements in oxygen delivery services and increased availability of portable oxygen concentrators.

Chronic obstructive pulmonary disease (COPD) oxygen therapy market Region

Segments

The Chronic Obstructive Pulmonary Disease(COPD) oxygen therapy market has been segmented on the basis of

Product Type

  • Portable Oxygen Concentrators
  • Stationary Oxygen Systems

Delivery Devices

  • Nasal Cannulas
  • Oxygen Masks
  • Venturi Masks
  • Non-rebreather Masks

Technology

  • Continuous Flow
  • Pulse Dose

Patient Age

  • Pediatric
  • Adult
  • Geriatric

End User

  • Hospital
  • Clinic
  • Homecare

Region

  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America

Key Players

Competitive Landscape

The competitive landscape of the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is shaped by several major players that offer a variety of products designed to meet the needs of individuals with COPD.

These players focus on innovations in oxygen delivery systems, such as portable oxygen concentrators, oxygen cylinders, liquid oxygen systems, and pulse dose therapy devices.


Market players including Philips Healthcare, Invacare Corporation, and Drive DeVilbiss Healthcare have a strong market presence with an emphasis on user-friendly and efficient devices.

They invest heavily in research and development, focusing on portability and patient comfort. Additionally, they engage in strategic partnerships and collaborations to expand their product offerings. The key players approach the market with global distribution and efficient, high-quality products in mind.

Chronic obstructive pulmonary disease (COPD) oxygen therapy market Keyplayers

 

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size & Forecast, 2023-2032
      4.5.1 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size and Y-o-Y Growth
      4.5.2 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Absolute $ Opportunity

Chapter 5 Global Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Analysis and Forecast By Product Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Product Type
      5.1.2 Basis Point Share (BPS) Analysis By Product Type
      5.1.3 Absolute $ Opportunity Assessment By Product Type
   5.2 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Product Type
      5.2.1 Portable Oxygen Concentrators and Stationary Oxygen Systems
   5.3 Market Attractiveness Analysis By Product Type

Chapter 6 Global Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Analysis and Forecast By Delivery Devices
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Delivery Devices
      6.1.2 Basis Point Share (BPS) Analysis By Delivery Devices
      6.1.3 Absolute $ Opportunity Assessment By Delivery Devices
   6.2 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Delivery Devices
      6.2.1 Nasal Cannulas
      6.2.2 Oxygen Masks
      6.2.3 Venturi Masks
      6.2.4 Non-rebreather Masks
   6.3 Market Attractiveness Analysis By Delivery Devices

Chapter 7 Global Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Analysis and Forecast By Technology
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Technology
      7.1.2 Basis Point Share (BPS) Analysis By Technology
      7.1.3 Absolute $ Opportunity Assessment By Technology
   7.2 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Technology
      7.2.1 Continuous Flow and Pulse Dose
   7.3 Market Attractiveness Analysis By Technology

Chapter 8 Global Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Analysis and Forecast By Patient Age
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By Patient Age
      8.1.2 Basis Point Share (BPS) Analysis By Patient Age
      8.1.3 Absolute $ Opportunity Assessment By Patient Age
   8.2 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Patient Age
      8.2.1 Pediatric and Adult
   8.3 Market Attractiveness Analysis By Patient Age

Chapter 9 Global Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Analysis and Forecast by Region
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities By Region
      9.1.2 Basis Point Share (BPS) Analysis By Region
      9.1.3 Absolute $ Opportunity Assessment By Region
   9.2 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Region
      9.2.1 North America
      9.2.2 Europe
      9.2.3 Asia Pacific
      9.2.4 Latin America
      9.2.5 Middle East & Africa (MEA)
   9.3 Market Attractiveness Analysis By Region

Chapter 10 Coronavirus Disease (COVID-19) Impact 
   10.1 Introduction 
   10.2 Current & Future Impact Analysis 
   10.3 Economic Impact Analysis 
   10.4 Government Policies 
   10.5 Investment Scenario

Chapter 11 North America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Analysis and Forecast
   11.1 Introduction
   11.2 North America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast by Country
      11.2.1 U.S.
      11.2.2 Canada
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 North America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Product Type
      11.6.1 Portable Oxygen Concentrators and Stationary Oxygen Systems
   11.7 Basis Point Share (BPS) Analysis By Product Type 
   11.8 Absolute $ Opportunity Assessment By Product Type 
   11.9 Market Attractiveness Analysis By Product Type
   11.10 North America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Delivery Devices
      11.10.1 Nasal Cannulas
      11.10.2 Oxygen Masks
      11.10.3 Venturi Masks
      11.10.4 Non-rebreather Masks
   11.11 Basis Point Share (BPS) Analysis By Delivery Devices 
   11.12 Absolute $ Opportunity Assessment By Delivery Devices 
   11.13 Market Attractiveness Analysis By Delivery Devices
   11.14 North America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Technology
      11.14.1 Continuous Flow and Pulse Dose
   11.15 Basis Point Share (BPS) Analysis By Technology 
   11.16 Absolute $ Opportunity Assessment By Technology 
   11.17 Market Attractiveness Analysis By Technology
   11.18 North America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Patient Age
      11.18.1 Pediatric and Adult
   11.19 Basis Point Share (BPS) Analysis By Patient Age 
   11.20 Absolute $ Opportunity Assessment By Patient Age 
   11.21 Market Attractiveness Analysis By Patient Age

Chapter 12 Europe Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Analysis and Forecast
   12.1 Introduction
   12.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast by Country
      12.2.1 Germany
      12.2.2 France
      12.2.3 Italy
      12.2.4 U.K.
      12.2.5 Spain
      12.2.6 Russia
      12.2.7 Rest of Europe
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Europe Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Product Type
      12.6.1 Portable Oxygen Concentrators and Stationary Oxygen Systems
   12.7 Basis Point Share (BPS) Analysis By Product Type 
   12.8 Absolute $ Opportunity Assessment By Product Type 
   12.9 Market Attractiveness Analysis By Product Type
   12.10 Europe Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Delivery Devices
      12.10.1 Nasal Cannulas
      12.10.2 Oxygen Masks
      12.10.3 Venturi Masks
      12.10.4 Non-rebreather Masks
   12.11 Basis Point Share (BPS) Analysis By Delivery Devices 
   12.12 Absolute $ Opportunity Assessment By Delivery Devices 
   12.13 Market Attractiveness Analysis By Delivery Devices
   12.14 Europe Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Technology
      12.14.1 Continuous Flow and Pulse Dose
   12.15 Basis Point Share (BPS) Analysis By Technology 
   12.16 Absolute $ Opportunity Assessment By Technology 
   12.17 Market Attractiveness Analysis By Technology
   12.18 Europe Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Patient Age
      12.18.1 Pediatric and Adult
   12.19 Basis Point Share (BPS) Analysis By Patient Age 
   12.20 Absolute $ Opportunity Assessment By Patient Age 
   12.21 Market Attractiveness Analysis By Patient Age

Chapter 13 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Analysis and Forecast
   13.1 Introduction
   13.2 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast by Country
      13.2.1 China
      13.2.2 Japan
      13.2.3 South Korea
      13.2.4 India
      13.2.5 Australia
      13.2.6 South East Asia (SEA)
      13.2.7 Rest of Asia Pacific (APAC)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Product Type
      13.6.1 Portable Oxygen Concentrators and Stationary Oxygen Systems
   13.7 Basis Point Share (BPS) Analysis By Product Type 
   13.8 Absolute $ Opportunity Assessment By Product Type 
   13.9 Market Attractiveness Analysis By Product Type
   13.10 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Delivery Devices
      13.10.1 Nasal Cannulas
      13.10.2 Oxygen Masks
      13.10.3 Venturi Masks
      13.10.4 Non-rebreather Masks
   13.11 Basis Point Share (BPS) Analysis By Delivery Devices 
   13.12 Absolute $ Opportunity Assessment By Delivery Devices 
   13.13 Market Attractiveness Analysis By Delivery Devices
   13.14 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Technology
      13.14.1 Continuous Flow and Pulse Dose
   13.15 Basis Point Share (BPS) Analysis By Technology 
   13.16 Absolute $ Opportunity Assessment By Technology 
   13.17 Market Attractiveness Analysis By Technology
   13.18 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Patient Age
      13.18.1 Pediatric and Adult
   13.19 Basis Point Share (BPS) Analysis By Patient Age 
   13.20 Absolute $ Opportunity Assessment By Patient Age 
   13.21 Market Attractiveness Analysis By Patient Age

Chapter 14 Latin America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Analysis and Forecast
   14.1 Introduction
   14.2 Latin America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast by Country
      14.2.1 Brazil
      14.2.2 Mexico
      14.2.3 Rest of Latin America (LATAM)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Latin America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Product Type
      14.6.1 Portable Oxygen Concentrators and Stationary Oxygen Systems
   14.7 Basis Point Share (BPS) Analysis By Product Type 
   14.8 Absolute $ Opportunity Assessment By Product Type 
   14.9 Market Attractiveness Analysis By Product Type
   14.10 Latin America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Delivery Devices
      14.10.1 Nasal Cannulas
      14.10.2 Oxygen Masks
      14.10.3 Venturi Masks
      14.10.4 Non-rebreather Masks
   14.11 Basis Point Share (BPS) Analysis By Delivery Devices 
   14.12 Absolute $ Opportunity Assessment By Delivery Devices 
   14.13 Market Attractiveness Analysis By Delivery Devices
   14.14 Latin America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Technology
      14.14.1 Continuous Flow and Pulse Dose
   14.15 Basis Point Share (BPS) Analysis By Technology 
   14.16 Absolute $ Opportunity Assessment By Technology 
   14.17 Market Attractiveness Analysis By Technology
   14.18 Latin America Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Patient Age
      14.18.1 Pediatric and Adult
   14.19 Basis Point Share (BPS) Analysis By Patient Age 
   14.20 Absolute $ Opportunity Assessment By Patient Age 
   14.21 Market Attractiveness Analysis By Patient Age

Chapter 15 Middle East & Africa (MEA) Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Analysis and Forecast
   15.1 Introduction
   15.2 Middle East & Africa (MEA) Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast by Country
      15.2.1 Saudi Arabia
      15.2.2 South Africa
      15.2.3 UAE
      15.2.4 Rest of Middle East & Africa (MEA)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Middle East & Africa (MEA) Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Product Type
      15.6.1 Portable Oxygen Concentrators and Stationary Oxygen Systems
   15.7 Basis Point Share (BPS) Analysis By Product Type 
   15.8 Absolute $ Opportunity Assessment By Product Type 
   15.9 Market Attractiveness Analysis By Product Type
   15.10 Middle East & Africa (MEA) Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Delivery Devices
      15.10.1 Nasal Cannulas
      15.10.2 Oxygen Masks
      15.10.3 Venturi Masks
      15.10.4 Non-rebreather Masks
   15.11 Basis Point Share (BPS) Analysis By Delivery Devices 
   15.12 Absolute $ Opportunity Assessment By Delivery Devices 
   15.13 Market Attractiveness Analysis By Delivery Devices
   15.14 Middle East & Africa (MEA) Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Technology
      15.14.1 Continuous Flow and Pulse Dose
   15.15 Basis Point Share (BPS) Analysis By Technology 
   15.16 Absolute $ Opportunity Assessment By Technology 
   15.17 Market Attractiveness Analysis By Technology
   15.18 Middle East & Africa (MEA) Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market Size Forecast By Patient Age
      15.18.1 Pediatric and Adult
   15.19 Basis Point Share (BPS) Analysis By Patient Age 
   15.20 Absolute $ Opportunity Assessment By Patient Age 
   15.21 Market Attractiveness Analysis By Patient Age

Chapter 16 Competition Landscape 
   16.1 Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market: Competitive Dashboard
   16.2 Global Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy  Market: Market Share Analysis, 2023
   16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      16.3.1 Abbott Drive DeVilbiss Healthcare F. Hoffmann-La Roche Ltd Fisher & Paykel Healthcare GE Healthcare GlaxoSmithKline (GSK plc.) Invacare Holdings Corporation Nidek Medical Products, Inc. Philips Respironics(Koninklijke Philips N.V.) OMRON Healthcare

Methodology

Our Clients

Deloitte
Dassault Aviation
Pfizer
sinopec
General Mills
Microsoft
The John Holland Group
Nestle SA